Commentary Adverse Drug Reactions of Multiple Sclerosis Disease-modifying Drugs

被引：0

作者：

Salehbayat, Maryam ^{[1
]}

Abolfazli, Roya ^{[2
]}

Mohebbi, Niayesh ^{[3
,4
]}

Savar, Seyed Mehrdad ^{[4
]}

Shalviri, Gloria ^{[4
]}

Gholami, Kheirollah ^{[3
,4
]}

机构：

[1] Univ Tehran Med Sci, Sch Pharm, Int Campus, Tehran, Iran

[2] Univ Tehran Med Sci, Amiralam Hosp, Dept Neurol, Tehran, Iran

[3] Univ Tehran Med Sci, Fac Pharm, Rat Use Drugs Res Ctr, Dept Clin Pharm, Tehran, Iran

[4] Univ Tehran Med Sci, Res Ctr Rat Use Drugs, Tehran, Iran

来源：

BASIC AND CLINICAL NEUROSCIENCE | 2023年 / 14卷 / 06期

关键词：

Adverse drug reactions; Interferons; Neuropharmacology; Neurology; Compliance;

D O I：

10.32598/bcn.2021.2848.2

中图分类号：

Q189 [神经科学];

学科分类号：

071006 ;

摘要：

Introduction: High frequency of adverse drug reactions (ADRs) challenges multiple sclerosis (MS) treatment. This study aims to assess the nature and frequency of ADRs induced by MS medications in an observational cross-sectional study. Methods: ADRs of all outpatients who had seen a neurologist and had received at least one disease-modifying therapy (DMT) for MS during the last three months were investigated. Results: A total of 484 ADRs were detected in these patients. The preventability rate was 5.9%, and 0.61% of reactions were serious. Conclusion: The high frequency of adverse drug reactions in this study shows a strong need for strategy planning to increase patients' adherence to treatment.

引用

页码：879 / 884

页数：6

共 50 条

[1] Risk Mitigation Strategies for Adverse Reactions Associated with the Disease-Modifying Drugs in Multiple Sclerosis
Adnan M. Subei
Daniel Ontaneda
[J]. CNS Drugs, 2015, 29 : 759 - 771
[2] Adverse Events Associated With Disease-Modifying Drugs for Multiple Sclerosis
Ng, Huah Shin
Zhu, Feng
Zhao, Yinshan
Yao, Shenzhen
Lu, Xinya
Ekuma, Okechukwu
Evans, Charity
Fisk, John D.
Marrie, Ruth Ann
Tremlett, Helen
[J]. NEUROLOGY, 2024, 102 (03)
[3] Risk Mitigation Strategies for Adverse Reactions Associated with the Disease-Modifying Drugs in Multiple Sclerosis
Subei, Adnan M.
Ontaneda, Daniel
[J]. CNS DRUGS, 2015, 29 (09) : 759 - 771
[4] Use of Disease-Modifying Drugs in Multiple Sclerosis
Wurzius, F. Q.
Silva, C. B.
de Vecino, M. A.
[J]. MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (1_SUPPL) : 102 - 103
[5] Postmarketing evidence of disease-modifying drugs in multiple sclerosis
Trojano, Maria
Paolicelli, Damiano
Fuiani, Aurora
Pellegrini, Fabio
Iaffaldano, Pietro
Direnzo, Vita
D'Onghia, Mariangela
[J]. NEUROLOGICAL SCIENCES, 2008, 29 (Suppl 2) : S225 - S226
[6] Monitoring the use of disease-modifying drugs in multiple sclerosis
Poluzzi, Elisabetta
Piccinni, Carlo
Sacripanti, Chiara
Tola, Maria Rosaria
D'Alessandro, Roberto
Montanaro, Nicola
[J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2008, 17 : S33 - S34
[7] Multiple Sclerosis Disease-Modifying Drugs in Children and Adolescents
Bykova O.V.
Nankina I.A.
Drozdova I.M.
Kvasova O.V.
Batysheva T.T.
Boiko A.N.
[J]. Neuroscience and Behavioral Physiology, 2017, 47 (5) : 544 - 552
[8] The Disability Outcomes of Disease-Modifying Drugs in Multiple Sclerosis
Hader, Walter
[J]. NEUROLOGY, 2012, 78
[9] Postmarketing evidence of disease-modifying drugs in multiple sclerosis
Maria Trojano
Damiano Paolicelli
Aurora Fuiani
Fabio Pellegrini
Pietro Iaffaldano
Vita Direnzo
Mariangela D’Onghia
[J]. Neurological Sciences, 2008, 29 : 225 - 226
[10] Disease-Modifying Drugs for Multiple Sclerosis and Association With Survival
Ng, Huah Shin
Zhu, Feng
Kingwell, Elaine
Yao, Shenzhen
Ekuma, Okechukwu
Evans, Charity
Fisk, John D.
Marrie, Ruth Ann
Zhao, Yinshan
Tremlett, Helen
[J]. NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2022, 9 (05):

← 1 2 3 4 5 →